A Comprehensive Monograph on Leucovorin (Folinic Acid): From Molecular Mechanisms to Clinical Practice

1.0 Drug Identification and Chemical Profile

1.1 Overview: A Dual-Role Folate Analog in Therapeutics

Leucovorin, known interchangeably as folinic acid, is a chemically reduced derivative of folic acid that occupies a unique and critical position in modern pharmacotherapy.[1] Its clinical utility is defined by two distinct and seemingly contradictory pharmacological roles. Primarily, it functions as a "rescue" agent, or antidote, administered to mitigate the severe, dose-limiting toxicities of folic acid antagonists, most notably the chemotherapeutic agent methotrexate.[1] In this capacity, it selectively protects healthy host cells from cytotoxic damage. Conversely, Leucovorin also serves as a chemopotentiator, purposefully administered to enhance the cytotoxic efficacy of fluoropyrimidine-based chemotherapy, such as 5-fluorouracil (5-FU), particularly in the treatment of colorectal cancer.[1] This monograph is structured around this central duality, exploring the molecular basis and clinical implications of these opposing functions.

The drug's history dates back to its 1948 discovery as an essential growth cofactor for the bacterium Leuconostoc citrovorum, leading to its original name, "citrovorum factor".[1] With a long history of clinical use, it received its initial approval from the U.S. Food and Drug Administration (FDA) in 1952, underscoring its enduring importance in medicine.[6]

1.2 Chemical Identity and Physicochemical Properties

Leucovorin is classified as a small molecule folate analog.[2] Its precise chemical identity and properties are fundamental to its biological activity.

• IUPAC Name: (2S)-2-{[(2-amino-5-formyl-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino] benzoyl]amino}pentanedioic acid.[1]
• Chemical Formula and Molecular Weight: The molecular formula is C20​H23​N7​O7​, corresponding to a molar mass of approximately 473.44 to 473.45 g/mol.[1]
• CAS Numbers: The Chemical Abstracts Service (CAS) has assigned several numbers related to Leucovorin, which can be a source of confusion. The primary CAS Registry Number for the free acid form is 58-05-9.[10] However, in clinical practice, it is most commonly administered as its calcium salt, which is identified by CAS number 1492-18-8.[1] Other relevant CAS numbers include 6035-45-6 for the calcium salt pentahydrate and 163254-40-8 for a sodium salt form.[6]
• Physical Properties: Leucovorin typically presents as a white to light yellow, amorphous or crystalline hygroscopic powder.[13] It has limited solubility in water, approximately 0.3 mg/mL at 20 °C, and decomposes at its melting point of 245 °C (473 °F).[1]

For clarity and ease of reference, the key chemical and physical identifiers for Leucovorin are consolidated in Table 1.1. This centralization is crucial for accurate substance identification in research, procurement, and regulatory contexts, particularly given the multiple CAS numbers associated with the drug and its various salt forms.

Table 1.1: Key Chemical and Physical Identifiers for Leucovorin

Identifier	Value	Source(s)
Common Names	Leucovorin, Folinic Acid, Citrovorum Factor	1
IUPAC Name	(2S)-2-{[(2-amino-5-formyl-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino] benzoyl]amino}pentanedioic acid	1
DrugBank ID	DB00650	1
CAS Number (Free Acid)	58-05-9	10
CAS Number (Calcium Salt)	1492-18-8	1
UNII	RPR1R4C0P4 (Calcium Salt)	1
PubChem CID	6006 (Free Acid)	1
ChEMBL ID	CHEMBL1679 (Free Acid)	1
ATC Code	V03AF03	1
Chemical Formula	C20​H23​N7​O7​	1
Molar Mass	473.446 g·mol⁻¹	1
Physical State	White to light yellow powder	13
Water Solubility	~0.3 mg/mL (20 °C)	1
Melting Point	245 °C (473 °F) with decomposition	1

1.3 Stereoisomerism: The Critical Distinction between Leucovorin and Levoleucovorin

A point of critical pharmacological importance is the stereochemistry of Leucovorin. The commercially available drug, often referred to simply as Leucovorin, is a racemic mixture containing equal amounts of two diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (THF): the dextrorotatory (d) and levorotatory (l) forms.[2]

Extensive research has demonstrated that only the levorotatory l-isomer, also known as (-)-folinic acid or levoleucovorin, is biologically active.[2] This is the isomer that can be metabolized and utilized by the body to participate in folate-dependent one-carbon transfer reactions. The d-isomer is pharmacologically inert and does not contribute to the therapeutic effect.[14]

This distinction led to the development and subsequent FDA approval in 2008 of levoleucovorin, a formulation containing only the pure, active l-isomer.[7] Reflecting its composition of 100% active drug, levoleucovorin is dosed at one-half the usual dose of racemic Leucovorin, possessing approximately twice the potency of the racemic mixture.[9]

The presence of the inactive d-isomer in racemic formulations creates a significant "pharmacokinetic burden." Pharmacokinetic studies reveal that the two isomers have vastly different fates in the body. The active l-isomer is rapidly metabolized and cleared, with a plasma half-life of about 32 minutes.[3] In contrast, the inactive d-isomer cannot be metabolized and is cleared much more slowly, exclusively through renal excretion, resulting in a half-life that is over ten times longer, at approximately 451 minutes.[14] This differential clearance leads to the accumulation and prolonged persistence of the inactive d-isomer in the plasma, where its concentrations can greatly exceed those of the active l-isomer and its metabolites.[15] While the d-isomer is considered pharmacologically inert, the sustained presence of a high concentration of any chemical entity is undesirable. It introduces a theoretical risk of competitive inhibition at cellular transport sites, unforeseen off-target effects, or an increased load on renal clearance mechanisms. This provides a compelling scientific and clinical rationale for the development and use of the pure active isomer, levoleucovorin, which delivers the intended therapeutic benefit without this unnecessary and prolonged chemical exposure.

2.0 Clinical Pharmacology

2.1 Pharmacodynamics: The Dichotomous Mechanism of Action

The clinical utility of Leucovorin stems from its role as a prodrug that is readily converted within the body to other biologically active reduced folate derivatives, such as 5,10-methylenetetrahydrofolate and 5-methyltetrahydrofolate (5-MTHF).[1] The defining feature of this process is that it completely bypasses the enzymatic step requiring dihydrofolate reductase (DHFR), the very enzyme targeted by a major class of antifolate chemotherapeutics.[1] This unique metabolic characteristic underpins Leucovorin's two primary, and opposing, pharmacodynamic functions.

2.1.1 Role as a Rescue Agent (Antidote Function)

Leucovorin's primary role as an antidote is in the context of high-dose methotrexate (MTX) chemotherapy.[1] Methotrexate functions by potently inhibiting the DHFR enzyme. This blockade prevents the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF), a critical step in the folate metabolic pathway. The resulting depletion of the cellular pool of reduced folates halts the

de novo synthesis of purines and thymidylate, which are essential precursors for DNA and RNA synthesis. This leads to cell cycle arrest and apoptosis, affecting not only rapidly dividing cancer cells but also healthy tissues with high turnover rates, such as bone marrow and gastrointestinal mucosa, causing severe toxicity.[1]

Leucovorin "rescues" these healthy cells by providing a direct source of reduced folates that is downstream of the MTX-induced enzymatic block. Once inside the cell, Leucovorin is converted to THF and other active derivatives, replenishing the coenzyme pool and allowing normal cells to resume nucleic acid synthesis and thus survive the otherwise lethal effects of high-dose MTX.[1] This strategy, known as "Leucovorin rescue," is a cornerstone of high-dose MTX therapy. The timing of administration is paramount; Leucovorin is typically given 24 hours

after the MTX infusion to allow the chemotherapeutic to exert its antitumor effect before the rescue of normal tissues begins.[3] The efficacy of the rescue diminishes markedly as the time interval from MTX administration increases.[17]

2.1.2 Role as a Chemopotentiator (Synergistic Function)

In stark contrast to its rescue function, Leucovorin acts as a powerful synergistic agent when combined with fluoropyrimidine chemotherapies, principally 5-fluorouracil (5-FU), in the treatment of malignancies like colorectal cancer.[1] The mechanism of this potentiation is well-defined. Inside the cell, 5-FU is converted to its active metabolite, fluorodeoxyuridine monophosphate (FdUMP). FdUMP exerts its cytotoxic effect by inhibiting the enzyme thymidylate synthase (TS), which is responsible for the synthesis of thymidylate, a necessary component of DNA.[3]

Leucovorin's role is to enhance and prolong this inhibition. It is metabolized within the cell to 5,10-methylenetetrahydrofolate (5,10−CH2​FH4​). This specific folate derivative acts as a molecular "glue," forming a highly stable ternary covalent complex with both FdUMP and the TS enzyme (the TS-FdUMP-5,10−CH2​FH4​ complex).[2] This stabilization effectively locks the enzyme in an inhibited state, leading to a more profound and sustained depletion of thymidylate and a corresponding enhancement of 5-FU's DNA-damaging and cytotoxic effects.[2]

2.1.3 Molecular Targets and Cellular Transport

The primary molecular target that Leucovorin's action is designed to circumvent is dihydrofolate reductase (DHFR).[2] In its potentiating role, the ultimate target of the Leucovorin/5-FU combination is

thymidylate synthase (TS).[2] Furthermore, Leucovorin utilizes and can compete with methotrexate for the same cellular transport systems, such as the reduced folate carrier and the proton-coupled folate transporter, which contributes to its rescue capabilities.[2]

2.2 Pharmacokinetics: A Comprehensive Profile

The clinical use of Leucovorin is profoundly influenced by its complex pharmacokinetic profile, which exhibits significant dependence on the route of administration and the stereochemistry of the formulation.

2.2.1 Absorption

Leucovorin is absorbed rapidly following oral administration, but this process is mediated by a saturable transport mechanism in the gastrointestinal tract.[3] This saturation has direct and critical clinical implications. The apparent bioavailability is highly dose-dependent: at a 25 mg dose, it is 97%, but this value decreases to 75% for a 50 mg dose and plummets to just 37% for a 100 mg dose.[16] This pharmacokinetic limitation is the scientific foundation for the clinical guideline that oral doses greater than 25 mg are not recommended, as they provide unreliable and disproportionately low systemic drug exposure.[3] For indications requiring high, predictable plasma concentrations, such as MTX rescue, parenteral administration is mandatory.

Furthermore, oral absorption is stereoselective, strongly favoring the active l-isomer. At a 25 mg dose, nearly 100% of the active l-isomer is absorbed, whereas only about 20% of the inactive d-isomer enters circulation.[15] The time to reach peak plasma concentration (Tmax) also varies by route: intravenous (IV) administration results in a peak of the parent compound in approximately 10 minutes, intramuscular (IM) administration peaks at around 52 minutes, and the oral route is the slowest, with a peak at approximately 2.3 hours.[16]

2.2.2 Distribution

Once absorbed, Leucovorin is widely distributed throughout the body tissues, with some concentration in the liver.[3] Its volume of distribution (Vd) is reported to be around 3.2 L/kg.[3] Plasma protein binding is relatively low, with reported values ranging from approximately 15% to 35-45%.[1] Leucovorin readily crosses the blood-brain barrier, primarily in the form of its active metabolite 5-MTHF. However, the resulting concentrations in the cerebrospinal fluid (CSF) are one to three orders of magnitude lower than the typical CSF concentrations of methotrexate following intrathecal administration.[3]

2.2.3 Metabolism

Leucovorin undergoes extensive and rapid metabolism. A significant portion of an oral dose is subject to first-pass metabolism in the intestinal mucosa and the liver, where it is converted to its primary active metabolite, 5-MTHF.[3] Consequently, 5-MTHF is the predominant circulating folate species following oral administration.[16] The metabolic pathway involves the conversion of the parent compound (5-formyl-THF) into other reduced folates, including 5,10-methenyl-THF and 5,10-methylene-THF (the key metabolite for 5-FU potentiation), before its eventual conversion to the terminal metabolite 5-MTHF.[1] This metabolism is specific to the active l-isomer; the inactive d-isomer is not metabolized and is cleared from the body unchanged.[14]

2.2.4 Excretion

The primary route of elimination for Leucovorin and its metabolites is via the kidneys, with 80-90% of a dose being excreted in the urine.[1] A smaller fraction, 5-8%, is eliminated in the feces.[3] The terminal elimination half-life (

t1/2​) for total reduced folates is approximately 6.2 hours.[1] However, this composite value masks the significant differences in the half-lives of the individual components: the active l-leucovorin has a very short half-life of about 32 minutes, its active metabolite 5-MTHF has a half-life of about 227 minutes (3.8 hours), and the inert d-leucovorin persists for a much longer duration with a half-life of about 451 minutes (7.5 hours).[3]

Table 2.1: Comparative Pharmacokinetic Parameters of Leucovorin by Route of Administration

Parameter	Oral Route	Intramuscular (IM) Route	Intravenous (IV) Route
Bioavailability	97% (25 mg), 75% (50 mg), 37% (100 mg) 16	Not applicable (assumed 100%)	Not applicable (100%)
Tmax (Parent Drug)	~1.2 hours 16	~28 minutes 16	~10 minutes 16
Cmax (Total Folates)	393 ng/mL (25 mg dose) 16	436 ng/mL (25 mg dose) 16	1259 ng/mL (25 mg dose) 16
Terminal Half-Life	~5.7 hours 16	~6.2 hours 16	~6.2 hours 1

The mechanistic duality of Leucovorin creates two entirely different sets of clinical imperatives and safety considerations. When used with methotrexate, its function is to reverse toxicity. The primary clinical risk is therefore under-dosing Leucovorin or administering it too late, which could lead to unchecked, life-threatening MTX toxicity.[17] Conversely, when used with 5-fluorouracil, its function is to enhance toxicity. Here, the primary clinical risk is

over-potentiation, which can lead to severe and potentially fatal 5-FU side effects like diarrhea and myelosuppression.[3] This means that for MTX protocols, clinicians must be vigilant in ensuring adequate Leucovorin levels, often monitoring MTX clearance and increasing the Leucovorin dose if necessary.[13] For 5-FU protocols, the opposite is true: clinicians must often reduce the dose of 5-FU and must monitor closely for signs of enhanced toxicity, being prepared to stop treatment immediately if severe gastrointestinal symptoms appear.[25] Leucovorin cannot be viewed as a simple vitamin supplement; its safe administration requires a sophisticated, context-dependent understanding of its interaction with its partner drug.

3.0 Therapeutic Indications and Clinical Efficacy

3.1 FDA-Approved Indications

Leucovorin has several well-established, FDA-approved indications that span both its antidote and chemopotentiation functions.[5]

3.1.1 Leucovorin Rescue after High-Dose Methotrexate Therapy

This is a cornerstone indication, particularly in the treatment of osteosarcoma and other malignancies where high-dose methotrexate regimens are employed.[2] The explicit purpose is to selectively "rescue" normal, healthy cells from the profound cytotoxic effects of methotrexate, thereby permitting the administration of tumoricidal drug levels that would otherwise be unacceptably toxic to the patient.[3]

3.1.2 Management of Folic Acid Antagonist Overdose and Impaired Elimination

Leucovorin is indicated to diminish the toxicity resulting from an inadvertent overdosage of methotrexate or other folic acid antagonists. It is also crucial for patients in whom methotrexate elimination is impaired due to factors such as pre-existing renal insufficiency, drug-induced nephrotoxicity, or the presence of third-space fluid accumulations (e.g., ascites, pleural effusion) that can act as a reservoir for the drug.[1]

3.1.3 Combination Therapy for Advanced Colorectal Cancer

In its role as a potentiator, Leucovorin is approved for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.[1] This indication is based on the synergistic mechanism that enhances the antitumor activity of 5-FU.

3.1.4 Treatment of Megaloblastic Anemia

Leucovorin is indicated for the treatment of megaloblastic anemias that arise from a deficiency of folic acid, specifically in situations where oral therapy with standard folic acid is not feasible.[1] This indication carries a critical caveat: pernicious anemia, which is a megaloblastic anemia caused by Vitamin B12 deficiency, must be definitively ruled out before initiating treatment.[1]

The indication for megaloblastic anemia highlights a significant clinical paradox. Using Leucovorin in a patient with an undiagnosed Vitamin B12 deficiency can have catastrophic consequences. Both folate and B12 deficiencies can present with the same hematologic finding: megaloblastic anemia, characterized by abnormally large and immature red blood cells.[1] Administering a folate, such as Leucovorin, can provide the necessary substrate to partially bypass the B12-dependent step in red blood cell maturation, thereby correcting the anemia and making the patient's blood work appear to improve.[1] However, this hematologic improvement masks the underlying B12 deficiency. Vitamin B12 is also independently critical for the maintenance of the myelin sheath that insulates nerve fibers. By "fixing" the anemia, Leucovorin can provide a false sense of security while the severe and often irreversible neurological damage of B12 deficiency—such as subacute combined degeneration of the spinal cord—progresses silently and unchecked.[5] This establishes a non-negotiable diagnostic mandate for clinicians: before treating any megaloblastic anemia with a folate product, Vitamin B12 deficiency must be ruled out as the primary cause.

3.2 Off-Label and Investigational Uses

Beyond its formal approvals, Leucovorin is widely used in other clinical contexts based on established practice and ongoing research.

• Role in Other Malignancies: As a potentiator of 5-FU, Leucovorin is a standard component of chemotherapy regimens for a variety of other gastrointestinal cancers, including pancreatic, gastric, esophageal, and anal cancers.[1] Historically, it has also been incorporated into regimens for breast and cervical cancer.[8]
• Prophylaxis for Drug-Induced Folate Deficiency: Leucovorin is commonly used to prevent hematologic toxicity from other, weaker folic acid antagonists. This includes its use alongside pyrimethamine for the treatment of toxoplasmosis and with trimethoprim, particularly when used in high doses.[1]
• Role in Non-Chemotherapeutic Contexts: Leucovorin has been used in the management of methanol poisoning, where it helps facilitate the metabolism of the toxic metabolite, formic acid.[1] It is also a treatment for cerebral folate deficiency, a rare neurological syndrome.[1]
• Emerging Research in Neurological and Developmental Disorders: A particularly novel area of investigation is the use of Leucovorin for treating core symptoms of Autism Spectrum Disorder (ASD). Several Phase 2 clinical trials are actively recruiting to evaluate its efficacy in improving language impairment and social deficits in young children with ASD.[32] It is also being studied for other rare neurological conditions like Hereditary Spastic Paraplegia.[33]

4.0 Safety, Tolerability, and Risk Management

4.1 Comprehensive Adverse Reaction Profile

The safety profile of Leucovorin is highly context-dependent, differing greatly based on whether it is used alone or in combination with a cytotoxic agent.

• Intrinsic Toxicity: When administered alone, Leucovorin is generally well-tolerated. The most frequently reported adverse events are related to allergic sensitization. These can range from mild skin reactions like urticaria (hives) to, in rare cases, more severe anaphylactoid reactions and fever.[1]
• Potentiation of Fluorouracil Toxicity: The most significant safety concerns arise from its combination with 5-fluorouracil. In this context, Leucovorin does not introduce new types of side effects but dramatically increases the incidence and severity of 5-FU's known toxicities.[3]
• Gastrointestinal Toxicity: Severe diarrhea and stomatitis (inflammation and ulceration of the mouth and gut lining) are the most common and dangerous toxicities. These can be dose-limiting and, particularly in elderly or debilitated patients, can lead to severe dehydration, enterocolitis, and death.[5]
• Hematological Toxicity: The myelosuppressive effects of 5-FU are enhanced, leading to higher rates of leukopenia (low white blood cells), neutropenia (low neutrophils), and thrombocytopenia (low platelets).[3]
• Dermatological Toxicity: The incidence or severity of hand-foot syndrome (palmar-plantar erythrodysesthesia) may be increased.[5]

4.2 Contraindications and Absolute Precautions

There are several situations where the use of Leucovorin is absolutely contraindicated due to the risk of severe harm.

4.2.1 The Critical Prohibition of Intrathecal Administration

This is the most severe warning associated with the drug. Intrathecal administration of Leucovorin is strictly contraindicated. This route of administration has been associated with severe adverse neurological events, including death.[1] This warning is based on case reports, such as that of an 11-year-old boy who suffered severe neurotoxicity after receiving intrathecal Leucovorin.[1]

4.2.2 Pernicious Anemia and Vitamin B12 Deficiency

As detailed previously, Leucovorin is contraindicated for the treatment of pernicious anemia or any other megaloblastic anemia resulting from Vitamin B12 deficiency. Its use can mask the hematologic signs of the disease while allowing irreversible neurological damage to progress unabated.[1]

4.2.3 Hypersensitivity

Leucovorin is contraindicated in any patient with a history of a severe hypersensitivity reaction to leucovorin, folic acid, or folinic acid products.[17]

4.3 Warnings, Precautions, and Clinical Monitoring

• Management of 5-FU Toxicity: Due to the risk of life-threatening gastrointestinal toxicity, therapy with the Leucovorin/5-FU combination must not be initiated or continued in patients who have active symptoms of stomatitis or diarrhea. Patients who develop diarrhea must be monitored with extreme care until it has completely resolved, as rapid clinical deterioration can occur.[19]
• Hypercalcemia Risk: The injectable formulations of Leucovorin contain calcium. Rapid intravenous injection of large doses can lead to transient hypercalcemia and potential cardiac arrhythmias. To mitigate this risk, the IV infusion rate should not exceed 160 mg of Leucovorin per minute.[3]
• Use in Special Populations:
• Geriatric: Elderly patients are at a significantly greater risk of developing severe, life-threatening toxicity from the Leucovorin/5-FU combination and require careful monitoring.[3]
• Pediatric: Leucovorin may increase the frequency of seizures in susceptible children, particularly those being treated with antiepileptic medications like phenobarbital or phenytoin.[3]
• Pregnancy and Lactation: While some classifications list it as relatively safe (e.g., Pregnancy Category A in Australia), adequate and well-controlled studies in pregnant women are lacking. It is frequently administered with known teratogens like methotrexate and 5-FU, so the risk profile of the entire regimen must be paramount. Due to the potential for secretion into breast milk, breastfeeding is generally not recommended during treatment.[1]

While a formal "Boxed Warning" from the FDA is not present on the Leucovorin label itself, the gravity of the warnings provided is functionally equivalent.[25] The language used to describe the risks of intrathecal administration ("death has been reported") and 5-FU potentiation ("rapid clinical deterioration leading to death can occur") conveys a level of danger on par with, or exceeding, that of many drugs with boxed warnings.[7] The absence of the specific black box format should not lead to any downplaying of these life-threatening risks. Clinicians and institutions must treat these warnings with the utmost seriousness, recognizing that the danger arises not from the drug in isolation, but from its specific use in a high-risk context or via an improper route of administration.

4.4 Significant Drug-Drug Interactions

Leucovorin's interactions with other drugs are clinically significant and central to both its efficacy and its toxicity profile.

Table 4.1: Clinically Significant Drug Interactions with Leucovorin

Interacting Drug/Class	Effect of Interaction	Mechanism	Management Recommendation
Fluoropyrimidines (5-Fluorouracil, Capecitabine)	Increased therapeutic and toxic effects of the fluoropyrimidine 3	Leucovorin metabolite (5,10−CH2​FH4​) stabilizes the inhibitory binding of FdUMP to thymidylate synthase 3	This is an intended interaction. Monitor closely for enhanced gastrointestinal and hematologic toxicity. The dose of 5-FU is often reduced when given with Leucovorin.19
Methotrexate	Decreased therapeutic and toxic effects of methotrexate 3	Leucovorin bypasses the DHFR enzyme block, replenishing the reduced folate pool. It may also compete for cellular transport.1	This is the intended "rescue" interaction. Administer Leucovorin after methotrexate. Monitor MTX levels to ensure adequate rescue.5
Antiepileptics (Phenobarbital, Phenytoin, Primidone)	Decreased efficacy of the antiepileptic drug, leading to increased seizure frequency 3	Mechanism is not fully known but may involve interference with folate-dependent microsomal metabolism of the antiepileptics.3	Primarily a concern with high doses of Leucovorin. Monitor for seizure control and consider checking antiepileptic drug levels.3
Trimethoprim/ Sulfamethoxazole	Increased rates of treatment failure and mortality when used for P. jiroveci pneumonia in HIV patients 18	The mechanism is not fully elucidated but suggests an antagonistic interaction in this specific clinical setting.	This combination should be used with caution or avoided for this indication.
Glucarpidase	Decreased plasma concentrations of Leucovorin 19	Glucarpidase is an enzyme that rapidly metabolizes both methotrexate and Leucovorin.20	Do not administer Leucovorin within two hours before or after a dose of glucarpidase to avoid its inactivation.20
Raltitrexed	Decreased efficacy of raltitrexed 3	Raltitrexed is a folate analogue that inhibits thymidylate synthase; Leucovorin may interfere with this action.	Co-administration is not recommended.3

5.0 Dosage, Administration, and Practical Considerations

5.1 Formulations and Brand Names

• Formulations: Leucovorin is available in multiple formulations to suit different clinical needs. These include oral tablets, typically in strengths of 5 mg, 10 mg, 15 mg, and 25 mg; a sterile solution for injection; and a lyophilized powder for reconstitution, intended for either intramuscular (IM) or intravenous (IV) administration.[21]
• Brand Names (United States): The original brand name for Leucovorin in the U.S. was Wellcovorin®.[6] Today, it is widely available as a generic medication from numerous manufacturers, including Teva and Meitheal Pharmaceuticals.[43] The pure l-isomer, levoleucovorin, is marketed under the brand names Fusilev® and Khapzory®.[27]
• Brand Names (International): Globally, Leucovorin is marketed under a vast array of brand names, reflecting its widespread use. Common international names include Antrex, Calcifolin, Lederfolin, Calfolex, Calinat, and Rescuvolin, among many others.[8]

5.2 Detailed Dosing Regimens by Indication

The dosing of Leucovorin is highly specific to the indication and, in the case of methotrexate rescue, is dynamically adjusted based on laboratory monitoring.

Table 5.1: Leucovorin Dosing Guidelines for Methotrexate Rescue

Clinical Situation	Laboratory Findings	Leucovorin Dose and Duration
Normal Methotrexate Elimination	Serum MTX level: ~10 µM at 24 hrs, ~1 µM at 48 hrs, and <0.2 µM at 72 hrs 13	15 mg (or ~10 mg/m²) IV/IM/PO every 6 hours for 10 doses (60 hours total), starting 24 hours after the start of the MTX infusion.13
Delayed Late MTX Elimination	Serum MTX level remains >0.2 µM at 72 hrs, and >0.05 µM at 96 hrs 30	Continue 15 mg (or 7.5 mg levoleucovorin) IV/IM every 6 hours until MTX level is <0.05 µM.30
Delayed Early MTX Elimination or Acute Renal Injury	24-hr serum creatinine increased ≥50% over baseline, OR 24-hr MTX level >5 µM, OR 48-hr MTX level >0.9 µM 23	Increase Leucovorin dose to 100-150 mg/m² IV every 3 hours until MTX level is <1 µM, then decrease dose to 15 mg IV every 3 hours until MTX level is <0.05 µM.7

• Colorectal Cancer (in combination with 5-FU): Dosing can vary significantly between protocols. Commonly cited regimens include Leucovorin 200 mg/m² as a slow IV injection followed by 5-FU, or a lower dose of 20 mg/m² IV followed by 5-FU.[36] The IFL (Irinotecan, Fluorouracil, Leucovorin) regimen uses a 20 mg/m² IV bolus of Leucovorin.[24] Clinicians must consult the specific therapeutic protocol being followed.
• Megaloblastic Anemia (due to folate deficiency): The recommended dose is up to 1 mg per day, administered IV or IM. There is no evidence that doses greater than 1 mg daily provide additional benefit.[7]
• Folic Acid Antagonist Overdose (non-MTX): To counteract toxicity from drugs like pyrimethamine or trimethoprim, a dose of 5 to 15 mg of Leucovorin per day is often recommended.[23] For managing pyrimethamine toxicity specifically in the treatment of toxoplasmosis, a dose of 3 to 9 mg IM daily may be used.[13]

5.3 Preparation, Handling, and Administration Protocols

Strict adherence to preparation and administration guidelines is essential for the safe and effective use of parenteral Leucovorin.

• Reconstitution: The lyophilized powder is typically reconstituted with either Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP. A critical exception exists: for doses greater than 10 mg/m², reconstitution must be done with Sterile Water for Injection (which does not contain the preservative benzyl alcohol) and the resulting solution must be used immediately.[16]
• Dilution and Stability: Once reconstituted, the solution can be further diluted for IV infusion in compatible solutions such as 5% Dextrose in Water (D5W) or 0.9% Sodium Chloride (Normal Saline). These diluted solutions are physically and chemically stable for 24 hours when stored under refrigeration (2 to 8°C).[13]
• Administration:
• Permitted Routes: Leucovorin can be administered orally, intramuscularly, by slow intravenous injection, or by intravenous infusion.[1]
• Forbidden Route: It must NEVER be administered intrathecally.[1]
• IV Infusion Rate: Due to the calcium content of the injectable solution, the rate of IV administration must not exceed 160 mg of Leucovorin per minute.[13]
• Incompatibilities: Leucovorin and 5-fluorouracil are physically incompatible and will form a precipitate if mixed in the same infusion bag or line. They must always be administered separately.[3]

6.0 The Evolving Landscape: Recent Clinical Trials and Future Directions

6.1 Analysis of Key Clinical Trials

While Leucovorin is a long-established drug, it remains an active area of clinical investigation, both for refining its role in oncology and for exploring novel applications.

• Role as a Backbone in Combination Regimens: Numerous clinical trials underscore Leucovorin's role as a foundational component of combination chemotherapy. Trials in colorectal cancer (CRC) such as NCT00942266 (evaluating the addition of vorinostat), NCT00217737 (evaluating the addition of bevacizumab to the FOLFOX regimen), and NCT00004931 (comparing FLOX to FL) all use a Leucovorin/5-FU combination as the standard backbone upon which new targeted therapies and biologics are tested.[51] The primary endpoint of the NCT00217737 trial in stage II CRC was 3-year disease-free survival, highlighting its importance in the adjuvant setting.[52]
• Exploration in Other Solid Tumors: The Phase I trial NCT00080990 investigated Leucovorin as part of a multi-drug regimen (with alvocidib and oxaliplatin) for a range of advanced solid tumors. The primary goal was to determine the maximum tolerated dose (MTD) of the combination, a typical objective for early-phase oncology trials.[55]
• Refining Rescue Therapy: Research continues to optimize Leucovorin's rescue function. Trial NCT00634504 was designed specifically to investigate the pharmacokinetic interaction between Leucovorin and glucarpidase, an enzyme that rapidly degrades methotrexate. This research aims to provide clearer guidance on how to administer rescue therapy when glucarpidase is used.[57]
• Novel Investigational Uses in Neurology: Perhaps the most exciting new frontier for Leucovorin is its investigation in neurodevelopmental disorders. The actively recruiting Phase 2 trials NCT04060017 and NCT04060030 are evaluating Leucovorin for the treatment of language and social deficits in children with Autism Spectrum Disorder (ASD).[32] This represents a significant conceptual leap for the drug, moving it far beyond its traditional domains of oncology and toxicology.

6.2 Unanswered Questions and Future Research

Despite decades of use, several key questions about Leucovorin remain, pointing toward future avenues of research:

• What is the precise neurobiological mechanism by which Leucovorin may exert a therapeutic effect on the core symptoms of Autism Spectrum Disorder?
• Does the "pharmacokinetic burden" imposed by the long-lasting, inactive d-isomer in racemic formulations have any subtle, long-term clinical consequences? Should the pure active isomer, levoleucovorin, be considered the standard of care in all settings?
• Can the potentiation of 5-fluorouracil be modulated to better separate its enhanced antitumor efficacy from its enhanced toxicity, perhaps through novel dosing schedules, alternative folate derivatives, or combination with novel cytoprotective agents?
• What is the exact molecular mechanism of the severe and fatal neurotoxicity observed following inadvertent intrathecal administration of Leucovorin? A deeper understanding could inform emergency management strategies.

7.0 Conclusion: Synthesis and Expert Perspective

7.1 Summary of Leucovorin's Role in Modern Therapeutics

Leucovorin is a mature yet indispensable therapeutic agent whose clinical value is defined by a remarkable pharmacodynamic paradox. In one context, it is a life-saving antidote, rescuing healthy tissues from the brink of chemotherapeutic devastation. In another, it is a powerful synergistic partner, intentionally used to amplify the cytotoxic potential of another drug. This dual nature makes it a unique and versatile tool in the pharmacopeia, but also one that demands a high level of clinical sophistication for its safe and effective use. Its long history, from its discovery as a bacterial growth factor to its current role as a cornerstone of complex cancer regimens and a potential therapy for neurodevelopmental disorders, speaks to its enduring relevance.

7.2 Concluding Remarks on Optimal Use and Future Research

The optimal and safe application of Leucovorin is entirely contingent on the clinician's deep understanding of its specific role within any given therapeutic regimen. Its use is not a one-size-fits-all proposition. Mastery of its complex pharmacokinetics—particularly the saturable nature of its oral absorption and the implications of its stereoisomerism—is essential for appropriate dose and route selection. Strict adherence to established administration protocols, especially the absolute prohibition of intrathecal use and the careful control of intravenous infusion rates, is non-negotiable for patient safety. Finally, vigilant clinical monitoring for context-specific toxicities, whether it be the risk of under-rescue from methotrexate or the risk of over-potentiation of 5-fluorouracil, is paramount. The future of Leucovorin will likely involve both the refinement of its use in oncology, potentially through the broader adoption of the purer levoleucovorin formulations, and the exciting exploration of its potential in non-oncological fields like neurology. This represents a potential new chapter for a drug that has already been a vital part of medicine for over half a century.

Works cited

1. Folinic acid - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Folinic_acid
2. Leucovorin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 16, 2025, https://go.drugbank.com/drugs/DB00650
3. DRUG NAME: Leucovorin - BC Cancer, accessed July 16, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Leucovorin_monograph.pdf
4. Folinic Acid - StatPearls - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545232/
5. leucovorin - Cancer Care Ontario, accessed July 16, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43961
6. Leucovorin Calcium | C20H21CaN7O7 | CID 135403647 - PubChem, accessed July 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Calcium%20leucovorin
7. Leucovorin - StatPearls - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK553114/
8. Leucovorin (Folinic acid) | HemOnc.org - A Hematology Oncology Wiki, accessed July 16, 2025, https://hemonc.org/wiki/Leucovorin_(Folinic_acid)
9. 1 INDICATIONS AND USAGE 1.1 Limitations of Use - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020140lbl.pdf
10. Leucovorin | CAS#58-05-9 | metabolite of folic acid - MedKoo Biosciences, accessed July 16, 2025, https://www.medkoo.com/products/17633
11. Folinic Acid | CAS 58-05-9 | SCBT - Santa Cruz Biotechnology, accessed July 16, 2025, https://www.scbt.com/p/folinic-acid-58-05-9
12. Leucovorin | C20H23N7O7 | CID 135403648 - PubChem, accessed July 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Leucovorin
13. LEUCOVORIN CALCIUM INJECTION - Pfizer, accessed July 16, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12786
14. Pharmacology Review(s) - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000PharmR.pdf
15. Pharmacokinetics of the Diastereoisomers of Leucovorin after Intravenous and Oral Administration to Normal Subjects1 - AACR Journals, accessed July 16, 2025, https://aacrjournals.org/cancerres/article-pdf/44/7/3114/2419752/cr0440073114.pdf
16. LEUCOVORIN CALCIUM INJECTION Label - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040347s010lbl.pdf
17. Leucovorin Calcium Injection - NPS MedicineWise, accessed July 16, 2025, https://www.nps.org.au/medicine-finder/leucovorin-calcium-injection-solution-for-injection
18. Leucovorin: Colon Cancer Uses, Side Effects, Dosage - MedicineNet, accessed July 16, 2025, https://www.medicinenet.com/leucovorin/article.htm
19. Leucovorin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 16, 2025, https://www.rxlist.com/leucovorin/generic-drug.htm
20. leucovorin dosing, indications, interactions, adverse effects, and more, accessed July 16, 2025, https://reference.medscape.com/drug/leucovorin-343736
21. Leucovorin (oral route, intravenous route, injection route) - Side effects & dosage - Mayo Clinic, accessed July 16, 2025, https://www.mayoclinic.org/drugs-supplements/leucovorin-oral-route-intravenous-route-injection-route/description/drg-20064503
22. Pharmacokinetics of Leucovorin Metabolites in Human Plasma as a Function of Dose Administered Orally and Intravenously, accessed July 16, 2025, https://academic.oup.com/jnci/article-pdf/83/24/1806/7804122/83-24-1806.pdf
23. Leucovorin Calcium Tablets, USP - DailyMed, accessed July 16, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94669fc8-3c1c-4228-be27-09a1cd468c36
24. leucovorin calcium - Drug Summary - PDR.Net, accessed July 16, 2025, https://www.pdr.net/drug-summary/Leucovorin-Calcium-Tablets-leucovorin-calcium-1570
25. FULL PRESCRIBING INFORMATION - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020140s024lbl.pdf
26. Data Sheet Template - Medsafe, accessed July 16, 2025, https://www.medsafe.govt.nz/profs/datasheet/l/leucovorincalciuminjtab.pdf
27. Leucovorin | Leukemia and Lymphoma Society, accessed July 16, 2025, https://lls.org/drug/leucovorin
28. Leucovorin - SEER*Rx Interactive Antineoplastic Drugs Database, accessed July 16, 2025, https://seer.cancer.gov/seertools/seerrx/rx/53c44b04102c1290262dcb04/
29. Leucovorin Calcium - NCI, accessed July 16, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/leucovorincalcium
30. KHAPZORY (levoleucovorin) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211226s000lbl.pdf
31. Leucovorin: MedlinePlus Drug Information, accessed July 16, 2025, https://medlineplus.gov/druginfo/meds/a682336.html
32. Leucovorin Recruiting Phase 2 Trials for Autism Spectrum Disorder / Language Impairment Treatment | DrugBank Online, accessed July 16, 2025, https://go.drugbank.com/drugs/DB00650/clinical_trials?conditions=DBCOND0006160%2CDBCOND0058279&phase=2&purpose=treatment&status=recruiting
33. Search for: leucovorin calcium | Card Results - ClinicalTrials.gov, accessed July 16, 2025, https://clinicaltrials.gov/search?intr=leucovorin%20calcium&viewType=Table&rank=4
34. Material Safety Data Sheet - Pfizer, accessed July 16, 2025, https://cdn.pfizer.com/pfizercom/products/material_safety_data/PZ00244.pdf
35. 40347 Leucovorin Calcium Final Print Label - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40347_Leucovorin%20Calcium_Prntlbl.pdf
36. Leucovorin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 16, 2025, https://www.drugs.com/dosage/leucovorin.html
37. CI 4820-1 - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/008107Orig1s051lbl.pdf
38. Leucovorin Calcium - GlobalRPH, accessed July 16, 2025, https://globalrph.com/oncology/leucovorin-calcium/
39. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020571s050lbl.pdf
40. ELOXATIN (oxaliplatin) injection, for intravenous use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021759s024lbl.pdf
41. Onivyde - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207793s016lbl.pdf
42. Reference ID: 3919201 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022160s010lbl.pdf
43. Leucovorin Calcium Tablets, USP - Teva Pharmaceuticals USA, accessed July 16, 2025, https://www.tevausa.com/our-products/tevagenerics/teva-generics-catalog/vision-product-page/leucovorincalciumtabletsusp
44. Leucovorin Calcium for Injection, USP - Wellcovorin - Meitheal Pharmaceuticals, accessed July 16, 2025, https://www.meithealpharma.com/our-products/64
45. Leucovorin: Uses, Side Effects, Interactions, Pictures, Warnings ..., accessed July 16, 2025, https://www.webmd.com/drugs/2/drug-1498/leucovorin-calcium-oral/details
46. Leucovorin - brand name list from Drugs.com, accessed July 16, 2025, https://www.drugs.com/ingredient/leucovorin.html
47. Leucovorin Interactions Checker - Drugs.com, accessed July 16, 2025, https://www.drugs.com/drug-interactions/leucovorin.html
48. Definition of leucovorin calcium - NCI Drug Dictionary, accessed July 16, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/leucovorin-calcium
49. Calcium Folinate (International database) - Drugs.com, accessed July 16, 2025, https://www.drugs.com/international/calcium-folinate.html
50. 3d24729d-b6e6-4878-aeb3-5507c19ee737.xml - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/spl/data/3d24729d-b6e6-4878-aeb3-5507c19ee737/3d24729d-b6e6-4878-aeb3-5507c19ee737.xml
51. Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment | ClinicalTrials.gov, accessed July 16, 2025, https://clinicaltrials.gov/study/NCT00942266
52. Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | ClinicalTrials.gov, accessed July 16, 2025, https://clinicaltrials.gov/study/NCT00217737
53. Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer | ClinicalTrials.gov, accessed July 16, 2025, https://clinicaltrials.gov/study/NCT00004931
54. Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer - UCSF Clinical Trials, accessed July 16, 2025, https://clinicaltrials.ucsf.edu/trial/NCT00217737
55. Study Details | Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors | ClinicalTrials.gov, accessed July 16, 2025, https://www.clinicaltrials.gov/study/NCT00080990?term=HMR%201275&rank=10
56. Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors | ClinicalTrials.gov, accessed July 16, 2025, https://clinicaltrials.gov/study/NCT00080990
57. Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze | ClinicalTrials.gov, accessed July 16, 2025, https://clinicaltrials.gov/study/NCT00634504